Type 2 Diabetes Mellitus Completed Phase 1 Trials for Dapagliflozin (DB06292)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

DBCOND0029752 (Type 2 Diabetes Mellitus)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01135446Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
NCT03138356Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsTreatment
NCT00839683Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
NCT00842556Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
NCT00908271Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
NCT00904176Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy SubjectsTreatment
NCT00930865Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy SubjectsTreatment
NCT01055652Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
NCT01165268Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)Basic Science
NCT01525238PK Study of Dapagliflozin in Pediatric Subjects With T2DM
NCT01535677To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered SeparatelyBasic Science
NCT01662999Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
NCT02060201Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
NCT02223065Bioequivalence Study Coadministered to Healthy Subjects in the Fasted StateBasic Science
NCT01002807Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
NCT02722239An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed ConditionsTreatment
NCT00538174Phase I Multiple-Ascending Dose (Japan)Treatment
NCT00554450Renal Impairment in Type 2 Diabetic SubjectsTreatment
NCT00562250Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy SubjectsTreatment